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Praziquantel has been the mainstay of schistosomiasis control since 1984 and widely distributed since 2006
through ‘preventive chemotherapy’ programmes to school-aged children or at-risk populations. In addition,
preschool-aged children are now recognized as a vulnerable population and a group for targeted treatment, but
they may be difficult to dose correctly with the available product—a racemate, based on the biologically active
enantiomer (R-praziquantel) and the inactive distomer (S-praziquantel), which contributes the bitter taste and
doubles the size of the tablets. Hence, a paediatric formulation is required, possibly enantiomerically pure. Devel-
oping such a product and extending its use to younger children should be pharmacologically guided, but limited
data exist on pharmacokinetics and pharmacokinetic/pharmacodynamic correlations for praziquantel. This
article presents available data on the chemistry, pharmacokinetics and pharmacodynamics of praziquantel, as
well as R-praziquantel, and points to gaps in our knowledge.
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Introduction
Some 779 million people are at risk of contracting schistosomiasis,1
a neglected tropical disease accounting for 3.3 million disability-
adjusted life years.2 Praziquantel is widely used for the treatment
and control of all Schistosoma species infecting humans and
causing the intestinal (mainly Schistosoma mansoni and Schisto-
soma japonicum) and urinary (Schistosoma haematobium) forms
ofschistosomiasis.3–5Adultmale–femalepairs reside inthemesen-
teric veins and layeggs, which sustain both the transmission and the
pathology. Schistosomiasis develops over many years and is charac-
terized by immunogenic inflammatory, granulomatous and fibrotic
reactions, which are provoked by trapped schistosome eggs in the
tissues.5 Whereas treatment is directed against the adult worms,
the effects of treatment are customarily assessed by counting the
eggs in the excreta (stools or urine), although new methods are
under development (see below).
Praziquantel has been the mainstay of schistosomiasis control
since 1984. As praziquantel is effective and normally has only
minor and transient side effects, it has been widely used since
2006 through ‘preventive chemotherapy’ programmes distributing
the drug to school-aged children or at-risk populations, depending
on prevalence rates. In 2010, 34 million individuals received prazi-
quantel as part of these programmes, mostly in sub-Saharan
Africa.6 It has been estimated that in 2018 as many as 235 million
people will be treated with praziquantel, equivalent to a projected
use of 645 million praziquantel tablets.6
Recently, there has been a renewed interest in studying better
formulations of praziquantel, especially for small children.7 This
stems, at least in part, from the fact that preschool-aged children
are now recognized as a vulnerable population and a group for tar-
geted treatment.6 – 8
The current product is a racemate, made of the biologically active
enantiomer [R-praziquantel (R-PZQ)] and the inactive distomer
[S-praziquantel (S-PZQ)], which contributes the bitter taste and
unnecessarily doubles the size of the tablets (factors that render
treatment less acceptable, especially to small children).9 Hence, a
paediatric formulation (e.g. orodispersible tablets) would be an im-
provement. There is evidence that enantiomerically pure R-PZQ
can be synthesized economically,10,11 which might facilitate the de-
velopment of a child-friendly formulation of R-PZQ. It should be
noted that praziquantel is registered for use in subjects aged
4 years or more,12 which means that that this product is technically
not authorized in young children. There may be safety concerns in
this age group, with very limited data to support or belie them. A
similar situation has been faced for the treatment of children
under 24 months of age with albendazole and mebendazole; open
discussions with the original producers and several national regula-
tory authorities concluded that the exclusion was due to a lack of in-
formation on the treatment of the age group and not to any report
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documenting, or suggesting, a particular risk of toxicity.13 In that
case, a thorough review of the available pharmacokinetic and
safety data concluded that benzimidazoles could be used for the
treatment of soil-transmitted helminthiasis in children aged
12 monthsandolder,andthatthehealthbenefitsappear tooverride
any potential risk associated with the administration of the drug.14
In order to optimize praziquantel treatment for preschool-aged
children, basic information on the drug safety and pharmacology
is required. However, limited data are available; only a handful of
reviews on praziquantel pharmacology have been published to
date15–19 and little is known on the pharmacokinetic/pharmacody-
namic correlations of praziquantel. This paper summarizes available
data on the chemistry, pharmacokinetics and pharmacodynamics
of praziquantel, as well as R-PZQ, and points to gaps in the
knowledge.
Chemistry and biopharmaceutics
Praziquantel {2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-
4H-pyrazino[2,1-a]isoquinolin-4-one} has a molecular weight of
312.3 and is a Class II drug both according to the Biopharmaceutics
Classification System [BCS; high permeability, low solubility
(0.4 mg/mL)] and the Biopharmaceutics Drug Disposition Classifi-
cation System (BDDCS; extensive metabolism, low solubility).20,21
The product currently registered and distributed is a racemate con-
taining equal proportions of R-(2)-PZQ (levorotatory, L-PZQ) and
S-(+)-PZQ (dextrorotatory, D-PZQ). The structural formulae are
depicted in Figure 1. While we are not aware of specific data for
R-PZQ, neither its solubility nor its permeability (passive diffusion)
are expected to differ significantly from the racemate.
Pharmacokinetics
Few pharmacokinetic studies have been performed with prazi-
quantel in humans, and none in the main target population
(school-aged children with urinary or intestinal schistosomiasis)
or in preschool-aged children. Pharmacokinetic studies using
R-PZQ have not been carried out to date. The main pharmacoki-
netic parameters of praziquantel after oral administration are
summarized in Table 1. Studies were conducted in healthy
normal volunteers (HNVs; including fasting and fed conditions), S.
mansoni-infected adult patients with varying degrees of liver
damage22,23 and S. haematobium-infected subjects,24 as well as
in S. japonicum-infected subjects.25,26 The doses administered
ranged from 5 to 50 mg/kg in HNVs, and from 25 to 40 mg/kg in
patients; the pharmacokinetics of 60 mg/kg have not been investi-
gated, although this dose has been used to treat infected patients.
Different commercial products (e.g. Distocidew, Biltricidew and
Cysticidew) were used in the pharmacokinetic studies. In addition,
some studies compared the main pharmacokinetic parameters of
various commercial formulations.27,28
Few studies compared directly different doses of praziquantel: 5,
10, 20, 50 mg/kg (Cysticidew)29 and 20 versus 40 mg/kg (Biltricidew
and Distocidew).27 Increases in AUC were not dose-proportional,
which may be explained by the fact that the first-pass metabolism
is dose-dependent with regard to capacity, with saturation of the
metabolic routes. AUC values differed across studies and brands,
which may be accounted for by interindividual variability and
pharmacogenetics, as well as different dissolution profiles and bio-
availability of products. Doubling the dose from 20 to 40 mg/kg pro-
duced a 2.7- and 1.4-fold net increase in AUC for Biltricidew and
Distocidew, respectively.27 The dose–response study on Cysticidew
by Leopold et al.29 unfortunately did not include 40 mg/kg, the
current WHO-recommended dose.
Since a parenteral human formulation does not exist, the abso-
lute bioavailability of praziquantel is not known. Studies in mono-
gastric animals indicate a strong first-pass effect and oral mean
absolute bioavailability of around 36%.
Absorption
The absorption of praziquantel is rapid (Tmax 2–2.6 h in HNVs with
Distocidew) and nearly complete (.80%) (Figure 2), but the sys-
temic bioavailability of praziquantel is low and varies considerably
between individuals. After the administration of 40 mg/kg to
fasted healthy adults, the t1/2 was reported to range from 2.2 to
8.9 h and the AUC from 2100 to 5400 ng.h/mL. Oral drugs have a
greater pharmacokinetic variability than drugs administered by
the intravenous route, explained by the blood flow at the absorp-
tion site, the absorptive surface area, the transit time and the
gastric pH,30 factors all influenced by concurrent food uptake.
The bioavailability of praziquantel increases with concomitant
food administration. Castro et al.31 showed that following the
administration of a dose of 1800 mg (25 mg/kg for a 70 kg
body weight) to healthy adults, the AUC0 – 8 was 2.7-fold higher
with a fatty diet (eggs, ham, orange juice, milk; 30% lipid;
50% carbohydrate) and4-fold higher with a high-carbohydrate
content diet (tortillas, tomato, chicken, bread, orange juice;10%
lipid;75% carbohydrate) than without food. Similarly, the admin-
istration to Sudanese adult males of praziquantel at a dose of
40 mg/kg with food (cooked beans/10% cotton seed oil/bread)
resulted in a 2.6-fold increase in the AUC0-1.
32 In addition, neuro-
cysticercosis patients receiving a high-carbohydrate diet had sig-
nificantly greater plasma levels than fasted patients.33 The effect
of food on the bioavailability of praziquantel may be due to
changes in hepatic blood flow, altered cytochrome P450 (CYP)
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Figure 1. Structural formulae of R-PZQ and S-PZQ.
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Table 1. Pharmacokinetic parameters of praziquantel observed in key studies conducted in humans
Reference Subjects (n) Product Dose (mg/kg) Cmax (ng/mL) Tmax (h) t1/2 (h) AUC (ng.h/mL)
Leopold et al.,29 1978a HNVs (fed) (6) Cysticide 5 48+13 2.75+0.34 1.70+0.14 167+51
HNVs (fed) (6) Cysticide 10 66+11 2.58+0.24 1.30+0.16 209+55
HNVs (fed) (6) Cysticide 20 250+25 2.08+0.38 1.18+0.09 645+93
HNVs (fed) (8) Cysticide 50 1319+441 1.88+0.36 1.19+0.10 3931+1432
Castro et al.,31 2000b HNVs (fast) (9) Cysticide 25 319+227 1.39+0.98 2.03+0.24 882+417
HNVs (fat) (9) Cysticide 25 1095+780 1.94+1.09 1.72+0.18 2475+1166
HNVs (carbohydrates) (9) Cysticide 25 1962+780 1.47+0.64 1.66+0.32 3276+970
Mandour et al.,22 1990c HNVs (fast) (6) Distocide 40 978+220 2.60+0.30 3.30+0.30 4089+1594
HNVs (fat) (6) Distocide 40 1570+328 2.70+0.30 2.50+0.40 5699+1576
HNVs (low fat) (6) Distocide 40 2093+382 2.00+0.40 2.30+0.40 7126+1781
Homeida et al.,32 1994d HNVs (fast) (9) Distocide 40 1018+321 1.89+0.23 2.1+0.29 2979+825
HNVs (fat) (7) Distocide 40 1708+297 2.47+0.60 2.26+0.20 7613+918
Mandour et al.,22 1990c HNVs (fast) (6) Distocide 40 249+41 2.10+0.70 8.90+1.20 2110+563
HNVs (fast) (6) Biltricide 40 823+2716 1.60+0.20 6.30+0.70 5409+1913
Mandour et al.,22 1990c HNVs (fast) (6) Distocide 40 978+220 2.60+0.30 2.30+0.40 3823+1563
S. mansoni patients (different grades
of periportal fibrosis) (fast) (9)
Distocide 40 1618+387 1.60+0.30 11.90+5.40 15928+5489
el Guinaidy et al.,231994d S. mansoni patients, normal liver
function (fast) (10)
Distocide 40 833+519 1.48+0.74 2.99+1.28 3023+590
S. mansoni patients, Child A (fast) (10) Distocide 40 931+577 1.37+0.61 4.66+2.77 3870+2435
S. mansoni patients, Child B (fast) (10) Distocide 40 1469+739 2.21+0.78 4.74+2.16 10720+5530
S. mansoni patients, Child C (fast) (10) Distocide 40 3573+1296 3.20+1.05 8.45+2.62 45350+17500
Metwally et al.,27 1995e HNVs (fast) (10) Biltricide 20 846+211 1.65+0.21 0.97+0.19 1303+276
HNVs (fast) (10) Distocide 20 558+75 2.60+0.53 1.24+0.41 1562+287
HNVs (fast) (10) Biltricide 40 1281+371 2.00+0.23 2.18+0.29 3550+883
HNVs (fast) (10) Distocide 40 685+88 1.72+0.40 2.78+0.46 2133+366
Kaojarern et al.,28 1989e HNVs (fed) (8) Biltricide 40 1614+170 1.93+0.22 NA 4830+322
HNVs (fed) (8) brand B 40 1625+207 1.72+0.26 NA 4407+398
HNVs (fed) (8) brand C 40 1247+123 2.14+0.22 NA 3910+179
HNVs (fed) (8) brand D 40 1007+150 2.81+0.37 NA 3374+366
Ofori-Adjei et al.,24 1988b HNVs (fast) (6) Biltricide 30 1213+844 1.75+0.30 2.7+1.60 3032+1443
S. japonicum patients (fast) (5) Biltricide 30 3124+1721 1.9+1.20 1.7+0.70 4085+3020
Watt et al.,26 1988f,g S. japonicum patients, normal liver function (13) Biltricide 60 2170+1140 2.5+1.70 1.7+0.80 8940+4250
S. japonicum patients, liver moderate (9) Biltricide 60 5010+2470 1.9+1.30 2.2+0.64 22880+15820
S. japonicum patients, liver severe (8) Biltricide 60 8195+4860 2.6+2.00 2.3+1.00 37770+24500
aMean+SEM; AUC0 – 24.
bMean+SD; AUC0 – 8.
cMean+SEM; AUC0 –1.
dMean+SD; AUC0 –1.
eMean+SEM; AUC not defined.
fMean+SD; AUC0 – 24.
gFast/fed conditions not stated.
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expression in response to the diet or changes in the first-pass
metabolism (Figure 2).34,35
Observed differences in the oral bioavailability might also be
explained by differences in the formulation. Three studies showed
a variable drug disposition following the administration of different
brands to HNVs.22,27,28 For example, Biltricidew showed a Cmax and
AUC 3.3 and 2.6 times those of Distocidew; the Tmax and t1/2 were
shorter (0.8 and 0.7 those of Distocidew) but the sample size was
small.22 Different products appear to have varying dissolution pro-
files and bioavailabilities. Kaojarern et al.28 showed that two pro-
ducts that revealed lower AUC values were characterized by a
longer disintegration time and lower dissolution.
Although only four studies have been conducted in patients,
disease status appears to increase exposure.22,23,25,26 In a study
comparing praziquantel disposition in HNVs and patients after
the administration of 40 mg/kg, Cmax and AUC were 1.7- and
4.2-fold higher in patients, the Tmax was shorter (0.6 times) and
the t1/2 was 5.2 times longer.
22 Data in HNVs are relevant as a pro-
portion of individuals receiving praziquantel preventative chemo-
therapy are not infected. The lower exposure in these subjects
accounts for the drug’s good tolerability.
In very young children, compared with older children, one might
expect slower rates of absorption, especially for drugs with limited
water solubility (such as praziquantel), that are related to develop-
mental changes in gastrointestinal motility, resulting in a longer
time required to achieve the maximal plasma concentration.36
Distribution
In non-clinical studies, praziquantel was found to distribute
throughout the body and concentrate especially in the liver and
kidneys. Concentrations higher than those in plasma were found in
the lung, pancreas, adrenal glands, pituitary and salivary gland.15
The volume of distribution is not known. Praziquantel crosses the
blood–brain barrier, explaining its effectiveness in neurocysticerco-
sis.37 Concentrations in breast milk are approximately one-fourth of
the plasma concentration.38
Praziquantel is highly protein-bound (80%, nearly exclusive to
albumin),39,40which makesthe levels of free drug subject to factors
such as nutrition and inflammation41 (and further explains the dif-
ferences seen between healthy volunteers and patients). It is also
possible that the fraction of free drug will be higher in very young
children (,1 year old), who have a lower amount of total plasma
proteins, including albumin.36
Metabolism
Praziquantel undergoes an extensive first-pass metabolism in the
liver by the CYP system (CYP1A2, CYP3A4, CYP2B1, CYP3A5 and
CYP2C19).15,39 This makes its pharmacokinetics susceptible to
variability due to: (i) interindividual pharmacogenetic differences;
(ii) interactions with drugs or substances taken concomitantly that
induceor inhibitspecific isoenzymesoftheCYPsystem(e.g. increased
exposure with cimetidine or grapefruit juice42 and decreased expos-
ure with the anti-epileptic CYP inducers carbamazepine and pheny-
toin43 or rifampicin44); and (iii) the condition of the liver function
(exposure increases with the severity of hepatic impairment22).
The metabolism of praziquantel is stereo-selective. Several
studies have analysed the metabolites of praziquantel in vivo
(mouse, rat and man) and invitro (rat and human liver microsomes).
Identified metabolites vary depending on the species and analytical
methods but are in general hydroxylation products containing one,
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Figure 2. Schematic diagram showing the principal characteristics of praziquantel absorption, distribution, metabolism and excretion (‘ADME’). GI,
gastrointestinal.
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two, or three hydroxyl groups. The precise structure of many of
these metabolites and the position of the hydroxyl group is still
unknown. Studies in rat hepatocytes have shown that the main
metabolites are cis- and trans-4′-hydroxypraziquantel, the first
being most abundant in the rat. The main metabolite in man is
trans-4-hydroxypraziquantel. S-PZQ also produces additional
monohydroxypraziquantel metabolites.45 A recent study46 identi-
fied up to nine metabolites of praziquantel, two dehydrogenated
and seven monohydroxylated metabolites, using human liver
microsomes; no dihydroxylated metabolites were found. Two
studies have examined the enantioselective kinetic disposition of
praziquantel in HNVs and reported AUCR/S ratios of 1.67
47 and
1.79–2.648 for 4′-hydroxypraziquantel. Differences may be due to
an enantioselective first-pass metabolism.
TheR-trans-4′-hydroxypraziquantel was found to have a similar
activity to R-PZQ on adult S. mansoni in vitro.49 On the other hand,
S. japonicum were less affected by trans-4′-hydroxypraziquantel
than praziquantel: spasmodic contractions were observed only
at a high concentration of 30 mg/mL. Since these levels are
not achieved in vivo, the authors concluded that trans-4′-
hydroxypraziquantel is not therapeutically relevant.50
The maturation of drug-metabolizing enzymes is delayed and
almost all liver metabolic processes are slower in infants than in
the older child and adult. The maturation of different Phase 1
and Phase 2 reactions (e.g. conjugation) may vary extensively.
Hence, a prolonged t1/2 of praziquantel might be expected in
young children, although further studies are warranted.36,51
Elimination
Elimination of praziquantel is essentially renal (80% within 4 days,
of which 90% occurs within 24 h);15 as the product is extensively
metabolized, ,0.01% is found in the urine as the parent com-
pound. No studies are available in patients with renal impairment.
Generally, it takes 6–12 months for the various renal functions of
an infant to reach adult values;51 the elimination of praziquantel
should therefore be similar in preschool-aged children and adults.
Pharmacodynamics
In vitro and in vivo activity of praziquantel
A concentration of 1 mg/mL praziquantel is effective against all
intramammalian stages of S. mansoni (7–48 days old; derived
from lungs, liver and mesentery).52 Praziquantel disrupts Ca2+
homeostasis in adult worms, which induces a spasmodic muscular
contraction and immobilization of the worm’s body.53 Worms
treated with 1 mg/mL praziquantel stop moving immediately, as
demonstrated by microcalorimetric studies.54 Adult worms are
slightly more susceptible to praziquantel (LC50 0.03 mg/mL at
72 h) than schistosomula (0.68 mg/mL at 72 h).55
High doses of praziquantel are needed to achieve a high reduc-
tion in worm burden inSchistosoma-infected rodents. For example,
in the S. mansoni mouse model, praziquantel given at 172 mg/kg
and 592 mg/kg is estimated to achieve reductions in worm
burden of 50% and 95%, respectively.56 A similar ED95 of
479 mg/kg was determined when the drug was administered
over 5 days.52 However, the therapeutic potency of praziquantel
can be increased by applying multiple oral doses at short intervals
on a single treatment day (ED95 200 mg/kg).
52 The tegument of the
worm suffers severe damage following praziquantel treatment,
which results in exposure of the worm’s antigens. The host
humoral immune response therefore plays an important role in
the activity of praziquantel, which is significantly less active in B
cell-depleted mice.57
Enantioselective in vitro and in vivo activity
A handful of studies have evaluated the anti-schistosomal activity
of R-PZQ and S-PZQ in vitro and in vivo. Xiao and Catto58 demon-
strated that spasmodic contractions and vacuolization of the
tegument of S. mansoni occurred at concentrations of 0.1 mM
praziquantel and 0.05 mM R-PZQ in vitro. In vivo studies were done
in S. japonicum-infected rabbits and mice and S. mansoni-infected
mice.58–61 R-PZQ was superior to S-PZQ against S. japonicum
in vivo.59,61 Findings reported on the activity of R-PZQ in
S. mansoni-infected mice are contradictory. While Xiao and Catto58
have documented a reduction in worm burden of 72% following
the administration of R-PZQ to S. mansoni-infected mice, a low
worm burden reduction of 32% (compared with 51% for S-PZQ)
was observed in another study.59 Similarly, S. mansoni recovered
from infected mice treated with R-PZQ showed no significant
damage of the reproductive organs and tegument, in contrast to
worms exposed to S-PZQ.60
Clinical findings on praziquantel and R-PZQ
The recommended treatment schedule for praziquantel is
20 mg/kg three times a day at 4 hourly intervals on a single day
(Biltricidew monograph; http://www.bayer.ca/files/BILTRICIDE-PM-
ENG-30NOV2007-116425-2.pdf). For practical reasons, the WHO
recommends 40 mg/kg in a single administration for all forms
of schistosomiasis in preventive chemotherapy programmes.62
Cochrane systematic reviews show a dose-effect for S. mansoni
in the range 20–40 mg/kg and no further efficacy increase
beyond 40 mg/kg63, while the dose–response curve in that dose
range appeared to be flat for S. haematobium.64 Although these
data cannot be strictly compared, in the S. mansoni trials included
in the Cochrane systematic review, the average failure rate
decreased with increasing doses (51%, 35%, 23% and 17% with
20, 30, 40 and 60 mg/kg).
A systematic review and meta-analysis identified 56 compara-
tive and non-comparative trials of praziquantel, of which 36 enrolled
7000 preschool- and school-aged children and adolescents
treated with 40 mg/kg praziquantel (P. Olliaro and J. Zwang, unpub-
lished data). A multivariate mixed-effect model with random effect
on the study site showed a significant relationship between age
and cure rate [but not egg reduction rate (ERR)] for S. mansoni and
S. japonicum, and no age effect for S. haematobium (although
preschool-aged children were not present in this group).
To date, three studies have evaluated the clinical activity of
R-PZQ, of which only one has used the common Kato–Katz
method in intestinal schistosomiasis and comparable R-PZQ and
praziquantel dosages.65 In this trial, 278 patients withS. japonicum
were treated with 20 mg/kg R-PZQ or 40 mg/kg praziquantel. Four
months post-treatment, cure rates of 94.8% and 97.1% were
observed for R-PZQ and praziquantel, respectively. Importantly,
significantly fewer adverse events were observed in patients
treated with R-PZQ.65,66
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Pharmacokinetic/pharmacodynamic correlations
It is challenging to derive pharmacokinetic/pharmacodynamic
estimates for anthelminthic drugs. The above-mentioned non-
clinical in vivo data indicate that the anti-schistosomal activity of
praziquantel is not related to the absolute Cmax but rather to the
duration of exposure. The peak/MIC ratio in mice was high
(.100), with the Cmax in the mouse plasma ranging from 10.7 to
33 mg/mL after receiving a 500 mg/kg dose,67 and much higher
levels in the mesenteric and portal veins, where the adult worms
reside (Figure 2). This means that adult worms will encounter prazi-
quantel before it is metabolized in the liver through first-pass. For
example, in S. japonicum-infected rabbits the concentration of
praziquantel in the portal venous plasma was 10-fold greater
than in the femoral venous plasma.68 Note that the location in
the lungs most likely explains the lower susceptibility of juvenile
worms to praziquantel. On the other hand, the time during which
the serum level exceeds the MIC is short (the t1/2 in mice is
1 h),67 and the therapeutic potency of praziquantel increases
by applying multiple oral doses at short intervals on a single treat-
ment day,52 which increases the duration of exposure.
Obviously, it is even more difficult to examine the pharmacoki-
netic/pharmacodynamic relationship in patients. The effects are
customarily measured by counting eggs (in the faeces or urine)—
a proxy for the viability of adult worms—and expressed as either
(i) the cure rate (the proportion of patients who are negative post-
treatment) or (ii) the ERR (the proportional reduction in the mean
egg counts of the patient population treated from pre- to post-
treatment); furthermore, ERR could be based on either arithmetic
or geometric mean egg counts.69 This approach has clear limita-
tions: the limited sensitivity of the methods in use (the Kato–
Katz being the most widely used technique) and the fact that it
does not detect direct effects on adult (or juvenile) worms.
Newer, more contemporary methods are being tested, such as
the circulating anodic antigen70 and the circulating cathodic
antigen levels,71 which should provide a more reliable and standar-
dized way of measuring efficacy and relating it to drug exposure.
Practical aspects of the development and deployment
of praziquantel
In the absence of robust data (which are, among others, to be gen-
erated by a consortium on paediatric praziquantel development),8
it is not possible at present to quantify the potential advantages of
an enantiomerically pure product over the racemic mixture.
A paediatric formulation (of either product) can indeed improve
the dosing accuracyand acceptability when used programmatical-
ly; practical dosing indications are also needed. The customary
method used by many control programmes is the dosing pole
(dosing based on height, rather than weight)—originally for children
.110 cm72 and recently extended to children .60 cm.73 Where
scales are available, adequate dosing (within the 40–60 mg/kg
range) is achieved with formulations containing 150 mg of the ra-
cemate using practical weight categories from 5 kg body weight.74
Conclusions
Scant information isavailableon the pharmacokinetic properties and
pharmacokinetic/pharmacodynamic relationship of praziquantel,
especially in children, the population chiefly affected by schisto-
somiasis, and hence those who are more intensely treated.
The need for this information is particularly acute now that
paediatric formulations are being developed and that youngerchil-
dren too are considered for targeted treatment.
In the few available studies, praziquantel disposition appears to
vary widely; factors such as the product and the subject (whether
healthy or infected, and fasting or fed) seem to influence the dis-
position, but direct comparisons are difficult to make.
Regarding the dose, unless the pharmacokinetic/pharmacody-
namic characteristics of praziquantel are studied more systematic-
ally, it will not be possible to understand whetherdose adjustments
are required for subjects of different ages, particularly small chil-
dren, and to have a pharmacologically guided dose selection for
new products.
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